SAN FRANCISCO - Eight noteworthy studies exploring key research in the treatment of genitourinary cancers will be presented at the 2018 Genitourinary Cancers Symposium, taking place February 8-10 at the Moscone West Building in San Francisco, California. These abstracts investigate several approaches to the treatment and management of prostate, kidney, and bladder cancers.

Experts in genitourinary cancers are available to comment on the studies below.

Abstract 3: PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).

Oral Abstract Session A
Thursday, February 8, 2018: 1:00 - 1:10 p.m. PT
The Moscone West Building, Level 2, Ballroom

Maha Hussain, MD, FACP, FASCO
Northwestern University
Chicago, Illinois


Rapid-Fire Abstract Session
Thursday, February 8, 2018: 5:15 - 5:25 p.m. PT
The Moscone West Building, Level 2, Ballroom

Renaud de Crevoisier
Centre Eugène Marquis
Abstract 163: A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.

Oral Abstract Session A
Thursday, February 8, 2018: 1:45 - 1:55 p.m. PT
The Moscone West Building, Level 2, Ballroom

Fatima Karzai, MD
National Cancer Institute at the National Institutes of Health
Bethesda, MD

Abstract 165: The FALCON trial: Impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer.

Rapid-Fire Abstract Session
Thursday, February 8, 2018: 5:45 - 5:55 p.m. PT
The Moscone West Building, Level 2, Ballroom

Eugene Jueren Teoh, MBBS, MRCP
Oxford Univeristy Hospital/NHS Foundation Trust
Oxford, United Kingdom

Abstract 166: Impact of USPSTF recommendations on utilization of PSA screening in Medicare beneficiaries.

Poster Session A
Thursday, February 8, 2018: 11:30 a.m. - 1:00 p.m. PT
Thursday, February 8, 2018: 5:15 - 6:15 p.m. PT
The Moscone West Building, Level 1, West Hall

Rahul Ramesh Khairnar
University of Maryland, Baltimore
Baltimore, Maryland

Abstract 407: Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).

Poster Session B
Friday, February 9, 2018: 12:15 - 1:45 p.m. PT
Friday, February 9, 2018: 6:00 - 7:00 p.m. PT
The Moscone West Building, Level 1, West Hall
Alison Jane Birtle, MRCP, FRCR, MD
Rosemere Cancer Centre, Royal Preston Hospital
Preston, United Kingdom

**Abstract 408:** *Selective bladder preservation with twice-daily radiation plus 5-flourouracil/cisplatin (FCT) or daily radiation plus gemcitabine (GD) for patients with muscle invasive bladder cancer: Primary results of NRG/RTOG 0712-A randomized phase 2 multicenter trial.*

General Session 5
Friday, February 9, 2018: 11:45 - 11:55 a.m. PT
The Moscone West Building, Level 2, Ballroom

John J. Coen, MD
21st Century Oncology
Providence, Rhode Island

**Abstract 579:** *Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).*

Oral Abstract Session C
Friday, February 9, 2018: 12:15 - 1:45 p.m. PT
Friday, February 9, 2018: 6:00 - 7:00 p.m. PT
The Moscone West Building, Level 1, West Hall

Michael B. Atkins, MD
Georgetown University Lombardi Comprehensive Cancer Center
Washington, DC

**2018 Genitourinary Cancers Symposium News Planning Team:**
Sumanta K. Pal, MD, American Society of Clinical Oncology (ASCO); Daniel A. Hamstra, MD, PhD, American Society for Radiation Oncology (ASTRO); and Katie Murray, DO, Society of Urologic Oncology (SUO)

[View the disclosures for the News Planning Team.](#)

**ATtribution to the 2018 Genitourinary Cancers Symposium is Requested in All News Coverage.**

###

**About the American Society for Radiation Oncology:**
The American Society for Radiation Oncology (ASTRO) is the world’s largest radiation oncology society, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. The Society is dedicated to improving patient care...
through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three peer-reviewed journals, the International Journal of Radiation Oncology • Biology • Physics (redjournal.org), Practical Radiation Oncology (practicalradonc.org) and Advances in Radiation Oncology (advancesradonc.org); developed and maintains an extensive patient website, RT Answers (rtanswers.org); and created the Radiation Oncology Institute (roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit www.astro.org, sign up to receive our news and follow us on our blog, Facebook and Twitter.

About ASCO:

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.

About the Society of Urologic Oncology:
The Society of Urologic Oncology (SUO) was created in 1984 to enable qualified members primarily interested in the care of patients with malignant genitourinary diseases to meet for the purpose of discussion, development, and implementation of ideas to improve care. The Society and its bylaws conform to the guidelines and bylaws of the American Urological Association (AUA).

The purpose of the SUO is to develop educational and research initiatives and to study issues in urologic oncology and provide physician statements that represent a state of the art assessment of these issues to other organizations.

The Society also provides a forum for identifying the urologic oncologist as a physician with specific expertise in the study and treatment of genitourinary malignancies. In recognition of the multidisciplinary efforts involved in the study and treatment of genitourinary malignancies, the Society seeks to incorporate multiple disciplines in achieving these goals. The Society supports the activities of multiple disciplines in the common objectives of seeking
an increased understanding and successful treatment of genitourinary malignancies.

The SUO seeks to improve the care of patients with malignant urologic disease and to provide a forum for the discussion of problems relating to malignant urologic disease. Our objectives include: 1) Stimulating research in and the teaching of urologic oncology, 2) Disseminating the principles of urologic oncology to the medical profession at large, 3) Bringing urologists into a Society whose work is entirely, or principally with malignant disease, 4) Being identified as the most qualified organization on matters relating to urologic oncology, and 5) Standardize fellowship training in urologic oncology.

Please visit our website or call (847) 264-5901 for more information on how to become a member.